Dienogest: Uma nova opção terapêutica em endometriose

Luís Bahamondes; Aroldo F. Camargos

Dienogest: Uma nova opção terapêutica em endometriose

Luís Bahamondes, Aroldo F. Camargos

In: Femina · 2012 · W3192176412

article OA: closed CC0 ⤵ 1 in-corpus citation Metadata only

Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher is the canonical location for the actual content. If you have institutional access, use "Find at my library".

View on OpenAlex

⚙ AI-generated summary by claude@2026-06, 2026-06-12 ⓘ

This paper reviews dienogest as a new therapeutic option for endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (25)

A dose‐ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis via openalex
Capsule summary via openalex
Danazol for pelvic pain associated with endometriosis via openalex
Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis via openalex
Diagnosis and management of endometriosis. via openalex
Dienogest, a selective progestin, reduces plasma estradiol level through induction of apoptosis of granulosa cells in the ovarian dominant follicle without follicle-stimulating hormone suppression in monkeys via openalex
Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study via openalex
Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial via openalex
Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile via openalex
Differences in characteristics among 1,000 women with endometriosis based on extent of disease via openalex
EPIDEMIOLOGY OF ENDOMETRIOSIS via openalex
Estradiol Valerate/Dienogest: A Novel Oral Contraceptive via openalex
Influence of Dienogest on Ovulation in Young Fertile Women via openalex
Medical and Surgical Therapies for Pain Associated with Endometriosis via openalex
Modern combined oral contraceptives for pain associated with endometriosis via openalex
Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis via openalex
Pharmacodynamic study of four oral dosages of dienogest via openalex
Quality of life in Brazilian women with endometriosis assessed through a medical outcome questionnaire. via openalex
Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment via openalex
The impact of endometriosis upon quality of life: a qualitative analysis via openalex
W2101417341 via openalex
W2123134517 via openalex
W2023365171 via openalex
W2095424038 via openalex
W2045458073 via openalex

Cited by (1)

Evaluation of endometriosis-associated pain and influence of conventional treatment: a systematic review 2015

Source provenance

openalex: last seen: 2026-06-10T17:14:06.276822+00:00

License: CC0 · commercial use OK

[1] A dose‐ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis via openalex

[2] Capsule summary via openalex

[3] Danazol for pelvic pain associated with endometriosis via openalex

[4] Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis via openalex

[5] Diagnosis and management of endometriosis. via openalex

[6] Dienogest, a selective progestin, reduces plasma estradiol level through induction of apoptosis of granulosa cells in the ovarian dominant follicle without follicle-stimulating hormone suppression in monkeys via openalex

[7] Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study via openalex

[8] Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial via openalex

[9] Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile via openalex

[10] Differences in characteristics among 1,000 women with endometriosis based on extent of disease via openalex

[11] EPIDEMIOLOGY OF ENDOMETRIOSIS via openalex

[12] Estradiol Valerate/Dienogest: A Novel Oral Contraceptive via openalex

[13] Influence of Dienogest on Ovulation in Young Fertile Women via openalex

[14] Medical and Surgical Therapies for Pain Associated with Endometriosis via openalex

[15] Modern combined oral contraceptives for pain associated with endometriosis via openalex

[16] Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis via openalex

[17] Pharmacodynamic study of four oral dosages of dienogest via openalex

[18] Quality of life in Brazilian women with endometriosis assessed through a medical outcome questionnaire. via openalex

[19] Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment via openalex

[20] The impact of endometriosis upon quality of life: a qualitative analysis via openalex

[21] W2101417341 via openalex

[22] W2123134517 via openalex

[23] W2023365171 via openalex

[24] W2095424038 via openalex

[25] W2045458073 via openalex